Influence of nicotine on choline-deficient, L-amino acid-defined diet-induced non-alcoholic steatohepatitis in rats

Hiroyuki Kanamori, Yukiomi Nakade *, Taeko Yamauchi, Kazumasa Sakamoto, Tadahisa Inoue, Takaya Yamamoto, Yuji Kobayashi, Norimitsu Ishii, Tomohiko Ohashi, Kiyoki Ito, Yoshio Sumida, Haruhisa Nakao, Yoshitaka Fukuzawa, Masashi Yoneda

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan

*ynakade@aichi-med-u.ac.jp

Abstract

Nicotine, a major compound in cigarette smoke, decreases food intake and body weight gain in mammals; however, the influence of nicotine on the progression of non-alcoholic steatohepatitis (NASH) remains controversial. This study aimed to investigate the effect of nicotine on NASH in rat models. Male Wistar rats were fed choline-deficient, L-amino acid-defined (CDAA) diet and treated with nicotine or saline. Food intake, body weight gain, presence of hepatic steatosis, inflammation, and fibrosis were assessed 6 weeks after the rats were fed CDAA diet. Hepatic branch vagotomy was performed to elucidate the mechanism through which nicotine affected steatohepatitis.

CDAA diet induced hepatic steatosis, inflammation, and fibrosis, as well as increased the expression of inflammation-related genes. Conversely, nicotine significantly attenuated food intake, body weight gain, and inhibited the CDAA-diet-induced hepatic steatosis, inflammation, and fibrosis, together with increased expression of inflammation-related genes. Hepatic branch vagotomy by itself decreased food intake, body weight gain, and attenuated the CDAA-diet-induced hepatic steatosis, but not inflammation. However, nicotine did not change the food intake, body weight gain, and CDAA diet-induced hepatic steatosis and inflammation in vagotomized rats. These results suggest that nicotine attenuates the CDAA-diet-induced hepatic steatosis and inflammation through the hepatic branch of the vagus nerve in rats.

Introduction

With the increased occurrence of the metabolic syndrome, the incidence of non-alcoholic fatty liver disease (NAFLD) has also dramatically increased in recent years, becoming a major health issue and the most common liver disease worldwide [1, 2]. Non-alcoholic steatohepatitis (NASH), which is characterized by steatosis, necroinflammation, and cytopathic changes, causes liver cirrhosis and lies within the NAFLD spectrum [3]. Although the pathogenesis of
NASH remains elusive, an accumulation of excess lipids in the liver may be a prerequisite for developing NASH [4].

Several therapeutic approaches for treating NASH have been reported; however, the only promising therapy thus far is reduction of body weight [5]. Nicotine, a major component of cigarettes, exerts various physiological effects in mammals. Nicotine administration in rodents decreases food intake and body weight gain, and increases energy expenditure; conversely, withdrawal of nicotine causes hyperphagia and body weight gain [6, 7]. Long-term administration of nicotine can increase insulin sensitivity in the obese rats with diabetes by decreasing glycogen content in the liver [8]. Conversely, nicotine can decrease hepatic blood flow in rats via the activity of endogenous endothelin-1 [9]. Carbon tetrachloride-induced acute liver injury in rats is exacerbated by the administration of nicotine [10]. Thus, nicotine exerts positive as well as negative effects on the physiology and pathophysiology; however, it is controversial whether nicotine has a negative impact on NASH.

A previous study on rats demonstrated that chronic administration of nicotine decreases food intake, obesity, and hepatic steatosis [11]. Furthermore, nicotine improves the serum lipid profile, and decreases inflammation and endoplasmic reticulum stress in rats with diet-induced obesity [11]. On the contrary, the hepatic branch of the vagus nerve plays an important role in regulating food intake [12]. The hepatic vagal nerve is one of the sensors of nicotine in the hepatoporal region [13]. In this study, we examined the influence of nicotine on food intake, body weight gain, histological changes in the liver, lipid metabolism, and inflammation in rats with choline-deficient, l-amino acid-defined (CDAA) diet-induced NASH. We also examined the involvement of the hepatic vagal nerve in nicotine-induced changes in food intake, hepatic steatosis, and inflammation in CDAA diet-fed rats.

Materials and methods

Substances and treatments

Nicotine was purchased from Sigma Aldrich (St. Louis, MO). The CDAA diet was used to induce NASH in the rat model; the choline-sufficient, l-amino acid-defined (CSAA) diet was used as a control diet. Both the diets were purchased in a powdered form from the Oriental Yeast Co. (Tokyo, Japan). An antibody against CD68, which is a marker for macrophages [14], was purchased from AbD Serotec (Oxford, UK). Anti-α-smooth muscle actin (α-SMA) monoclonal antibody was purchased from Abcam (clone 1A4, Cambridge, MA).

Animal model and experimental design

Six-week-old male Wistar rats were purchased from Japan SLC Inc. (Hamamatsu, Japan). The rats were acclimatized in cages under conditions of controlled temperature (22–24˚C), humidity, and illumination (12 hour light cycle starting at 6:00 am) for at least 7 days before undergoing the experiments. After 1-week acclimatization period on a basal diet (Oriental Yeast), the rats were divided into four groups (6–8 rats/group) and then osmotic minipumps (Alzet model 2006, Alza; Palo Alto, CA), containing nicotine or saline, were implanted by an interscapular incision into the subcutaneous space of the back under isoflurane anesthesia. Next, the rats were fed with CDAA or CSAA diet, and nicotine (12 mg/kg/day) or saline (3.6 μL/day) was co-administered continuously via the minipumps for 6 weeks. The dose of nicotine was determined according to a previous report [15]. All the rats were provided with free access to water and experimental diets. Body weights and food intake in each group of rats were recorded every week and every day, respectively. Protocols describing the use of rats were approved by the Institutional Animal Care and Use Committee of the Aichi Medical University and were in accordance with the National Institutes of Health "Guide for the Care and Use
of Laboratory Animals." All rats were euthanized 6 weeks after the commencement of CSAA or CDAA diet using CO$_2$ inhalation. The liver from all the rats was immediately collected, weighted, and stored at −80°C for RNA extraction. Blood samples were collected from the left ventricle and centrifuged; plasma was stored at −80°C for subsequent analyses.

To investigate nicotine-induced alteration of CDAA-induced steatohepatitis, hepatic branch vagotomy or a sham operation was performed under isoflurane anesthesia 1 week before the implantation of osmotic minipumps. Hepatic branch vagotomy was performed under a dissection microscope by selective sectioning of the hepatic branch of the vagal nerve, which diverges from the anterior vagal trunk a few millimeters proximal to the cardia. One week after hepatic branch vagotomy, rats were subcutaneously implanted in the back with osmotic minipumps containing nicotine or saline; the procedure was conducted under isoflurane anesthesia. Next, rats were administered the CDAA diet for 6 weeks, after which the effects of hepatic branch vagotomy on body weight gain, hepatic steatosis, and inflammation were assessed.

**Assessment of hepatic steatosis, inflammation, fibrosis, and Kupffer cells**

Hepatic steatosis was assessed by monitoring the levels of hepatic triglycerides (TG), free fatty acid (FFA), and Oil Red O staining. Stored liver samples (100 mg) were lysed and homogenized, using a Polytron homogenizer (NS-310E; MicroTech Nichion, Tokyo, Japan), for 1 min in 2 mL solution containing 150 mM NaCl, 0.1% TritonX-100, and 10 nM Tris. TG and FFA levels in the liver were measured using the Triglyceride Detection Kit (Wako, Osaka, Japan) and non-esterified fatty acid Detection Kit (Wako, Osaka, Japan), respectively. Oil Red O staining was also performed on the frozen liver tissue samples using standard techniques. To evaluate the extent of hepatic inflammation and fibrosis, hematoxylin and eosin staining and Masson’s trichrome staining was performed on formalin-embedded 5-μm thick sections of the liver tissue respectively. Levels of TG and alanine aminotransferase (ALT) in the serum were measured using commercially available kits (Wako). The degree of hepatic steatosis, inflammation, and hepatocellular ballooning were assigned a score from 0 to 3, based on a histological scoring system for NAFLD established by Kleiner et al. [16]. For semiquantitative morphometric analysis of hepatic steatosis and fibrosis, the area stained with Oil Red O and Masson’s trichrome staining was quantified by a computerized image analysis system, Image-Pro Plus version 4.5 (Media Cybernetics, Silver Spring, MD), at 50× magnification using five randomly selected fields per section, respectively. Formalin-fixed paraffin-embedded liver sections were used for immunohistochemical analysis. After deparaffinization and rehydration in xylene and a graded series of alcohol, endogenous peroxidase was blocked with hydrogen peroxide. Non-specific binding was blocked with 10% normal goat serum in phosphate buffered saline. After blocking, the sections were incubated overnight with the anti-CD68 mouse monoclonal antibody diluted at 1:200, and the anti-α-SMA monoclonal antibody diluted at 1:1000. CD68-positive and αSMA-positive cells were counted under the light microscope using five fields per slide at 50× magnification and average counts were noted.

**Analysis of mRNA from the liver tissues by real-time polymerase chain reaction**

The frozen liver specimens were pulverized in TRIzol (Life Technologies, Tokyo, Japan). RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Tokyo, Japan). RNA was resuspended in 40 μL RNase-free water and quantified using the OD260 spectrophotometer and low-mass gel electrophoresis (Invitrogen, Tokyo, Japan). Total RNA was reverse-transcribed
to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. Real-time polymerase chain reaction (qPCR) was conducted on Step One Sequence Detection System (Applied Biosystems) using TaqMan Gene Expression Assays; the TaqMan probe IDs are listed in Table 1. TaqMan Universal PCR Master Mix (Applied Biosystems) was used according to the manufacturer’s instructions. The expression of the genes involved in the hepatic lipid metabolism, such as apolipoprotein B (apoB), microsomal triglyceride transfer protein (MTTP), stearoyl-element binding protein 1 (SREBP1), acyl-coenzyme A oxidase 1 (ACOX1), and elongation of very long chain fatty acids-like 6 (Elovl6), was assessed. To examine the degree of the inflammatory response, we also assessed the expression of the macrophage surface marker, CD68, and that of tumor necrosis factor-α (TNF-α), interleukin (IL)1β, and IL6 at the mRNA level. To examine the involvement of apoptosis, we also assessed the expression of Bcl2-associated X protein (Bax) and caspase 3 (Cas3) at the mRNA levels. To examine the hepatic stellate cell activation, alpha-smooth muscle actin 2 (ACTA2) expression was measured at the mRNA level. The relative levels of mRNA transcripts were quantified using the 2^ΔΔCT method. The variation in the amount of available DNA in the samples was controlled by normalizing the levels of the target sequence to those of the endogenous control, 18s ribosomal RNA, using the 18s rRNA TaqMan Control Reagent Kit (Applied Biosystems). The expression of target genes was normalized to that of 18s ribosomal RNA in each sample, and expressed as the magnitude of change relative to gene expression after 6 weeks of feeding CSAA or CDAA diet co-administered with saline. The conditions for qPCR were similar to those outlined in a previous report [17].

### Data analysis

All data are expressed as means ± SE. The values in the two groups were compared using Student’s t-test. Multiple group comparison was performed using analysis of variance (ANOVA) followed by Fisher’s protected least significant difference post-hoc test; a p value < 0.05 was considered statistically significant.

### Results

The CDAA-diet-fed rats co-administered with saline showed a significantly reduced body weight gain compared to that of CSAA-diet-fed rats co-administered with saline (Table 2), whereas the food intake of the CDAA diet-fed rats co-administered with saline was

---

**Table 1. Taqman probe ID for real time PCR.**

| Gene   | Gene bank number | Taqman ID                   |
|--------|------------------|-----------------------------|
| ApoB  | NM_019187        | Rn01499054_m1               |
| MTTP  | NM_001107727     | Rn01522963_m1               |
| SREBP1| NM_001276708     | Rn01495769_m1               |
| Elovl6| NM_134383        | Rn00592815_m1               |
| ACOX1 | NM_017340        | Rn01759925_g1               |
| CD68  | NM_001031638     | Rn01495634_g1               |
| TNF-α | NM_02675         | Rn00562055_m1               |
| IL1β  | NM_031512        | Rn00580432_m1               |
| IL6   | NM_02589         | Rn01410330_m1               |
| Bax   | NM_017059        | Rn01480161_g1               |
| Cas3  | NM_02922         | Rn00563902_m1               |
| Acta2 | NM_031004.2      | Rn01759928_g1               |

---

https://doi.org/10.1371/journal.pone.0180475.t001
comparable to that of CSAA-diet-fed rats co-administered with saline (Table 2). While the CSAA diet did not induce hepatic steatosis, the CDAA diet induced hepatic steatosis, which was assessed by the levels of hepatic TG and Oil Red O staining (Table 2, Table 3, Fig 1A and 1B). The levels of hepatic TG and FFA in CDAA-diet-fed rats co-administered with saline were significantly higher than those in CSAA-diet-fed rats co-administered with saline (Table 2). On the contrary, the serum levels of TG in CDAA-diet-fed rats co-administered with saline were significantly lower than those in CSAA-diet-fed rats co-administered with saline (Table 2). Serum levels of ALT in CDAA-diet-fed rats co-administered with saline were significantly higher than those in CSAA-diet-fed rats co-administered with saline (Table 2).

Nicotine administration attenuated food intake and body weight gain; however, it could not change the levels of serum ALT and hepatic TG in CSAA-diet-fed rats (Table 2). Nicotine administration significantly attenuated food intake, body weight gain, and hepatic fat deposition, which was confirmed by the area stained with Oil Red O, and increased levels of hepatic TG and FFA in CDAA-diet-fed rats (Table 2, Fig 1A and 1B). The decreased serum levels of TG and increased serum levels of ALT were not significantly altered by nicotine administration in CDAA-diet-fed rats (Table 2).

CDAA diet significantly attenuated the hepatic expression of \textit{apoB} at the mRNA levels, which was not changed by nicotine administration (Fig 2A). CDAA diet could not change the hepatic expression of \textit{MTTP} at the mRNA levels, which was also not changed by nicotine administration (Fig 2B). While nicotine administration could not change the hepatic expression of \textit{SREBP1} at the mRNA levels in control diet-fed group, CDAA diet significantly decreased the hepatic expression of \textit{SREBP1} at the mRNA levels, which was significantly attenuated by nicotine administration, in the CDAA diet-fed group (Fig 2C). While nicotine administration could not change the hepatic expression of \textit{Elov6} at the mRNA levels in the control diet, CDAA diet significantly decreased the hepatic expression of \textit{Elov6} at the mRNA levels in the CDAA diet-fed group (Table 2).

### Table 2. Clinical characteristics of rats after 6 weeks feeding of experimental diets.

| Group          | n  | Body Weight gain (g) | Food Intakes (g/day) | Serum TG (mg/dl) | Hepatic TG (mg/dl) | Hepatic FFA (mEq/l) | Serum ALT (IU/L) |
|----------------|----|----------------------|----------------------|-----------------|-------------------|-------------------|-----------------|
| CSAA + saline  | 6  | 145 ± 5.0            | 11.9 ± 1.9           | 150 ± 14        | 67 ± 5.8          | 0.7 ± 0.1         | 24 ± 2.0        |
| CSAA + nicotine| 6  | 136 ± 2.7           | 10.5 ± 0.5           | 174 ± 29        | 68 ± 4.8          | 0.8 ± 0.1         | 30 ± 4.2        |
| CDAA + saline  | 7  | 82 ± 3.2            | 12.3 ± 1.5           | 25 ± 1.2        | 653 ± 129         | 1.3 ± 0.3         | 204 ± 14.7      |
| CDAA + nicotine| 8  | 68 ± 3.8            | 10.1 ± 1.7           | 24 ± 1.5        | 440 ± 20          | 0.3 ± 0.1         | 190 ± 15.7      |

Data are expressed as means ± SEM; Statistical comparison were made using one-way ANOVA

\( ^a \): significant different from CSAA+saline 6 weeks (p < 0.05)

\( ^b \): significant different from CSAA+saline 6 weeks (p < 0.01)

\( ^c \): significant different from CDAA+saline 6 weeks (p < 0.05)

https://doi.org/10.1371/journal.pone.0180475.t002

### Table 3. NAFLD activity scores (NAS) of rats fed experimental diets with nicotine.

| Group          | n  | steatosis | inflammation | Hepatocyte ballooning |
|----------------|----|-----------|--------------|-----------------------|
| CSAA + saline  | 6  | 0 ± 0     | 0 ± 0        | 0 ± 0                 |
| CSAA + nicotine| 6  | 0 ± 0     | 0 ± 0        | 0 ± 0                 |
| CDAA + saline  | 7  | 2.667 ± 0.042\(^a\) | 1.600 ± 0.225\(^a\) | 0.233 ± 0.033\(^a\) |
| CDAA + nicotine| 8  | 2.375 ± 0.139\(^b\) | 1.200 ± 0.256\(^b\) | 0.100 ± 0.038\(^b\) |

Data are expressed as means ± SEM; Statistical comparison were made using one-way ANOVA

\( ^a \): significantly different from CSAA+saline (p < 0.01)

\( ^b \): significantly different from CDAA+saline (p < 0.05)

https://doi.org/10.1371/journal.pone.0180475.t003
levels, which tended to be decreased by nicotine administration, in the CDAA diet-fed group (Fig 2D). CDAA diet could not change the hepatic expression of ACOX1 at the mRNA levels, which was also not changed by nicotine administration (Fig 2E).

While the CSAA diet could not induce hepatic inflammation, CDAA diet induced hepatic inflammation, as assessed by the inflammation score (Table 3, Fig 3A). CDAA diet increased the hepatic expression of TNF-α, CD68, IL1β, IL6, Bax, and Cas3 at the mRNA level, as well as
the number of CD68-positive cells, compared to that in the CSAA diet-fed rats co-administered with saline (Fig 3B, Fig 4A and 4B). While ballooned hepatocytes were not observed in CSAA diet-fed rats treated with saline, CDAA diet-fed rats showed presence of the ballooned hepatocytes (Table 3). Nicotine administration did not affect hepatic inflammation, hepatocyte ballooning scores, expression of TNF-α, CD68, IL1β, IL6, Bax, and Cas3 at the mRNA level, or number of CD68-positive cells in CSAA-diet-fed rats (Table 3, Fig 3A and 3B, Fig 4A and 4B), whereas it significantly attenuated these parameters in CDAA-diet-fed rats. (Table 3, Fig 3A and 3B, Fig 4A and 4B). Nicotine administration also tended to decrease Cas3 expression at the mRNA level (Fig 3B). While the CSAA diet did not induce hepatic fibrosis, CDAA diet induced hepatic fibrosis as assessed by Masson’s trichrome stain-positive area (Fig 5A and 5B). CDAA diet increased the hepatic expression of Acta2 at the mRNA level, as well as the number

Fig 2. Evaluation of hepatic lipid metabolism-related gene expressions in CSAA- and CDAA- diet-fed rats. The relative mRNA expression of apoB (A), MTTP (B), SREBP1 (C), Elov6 (D) and ACOX1 (E) were evaluated 6 weeks after the commencement of CSAA and CDAA diets. The expression of target genes was normalized to that of 18s ribosomal RNA in each sample, and expressed as the magnitude of change relative to gene expression after 6 weeks of feeding CSAA diet co-administered with saline. The values are means ± SE of six to eight rats. Statistically significant differences between the respective groups are indicated as * p < 0.05, ** p < 0.01.
Fig 3. Evaluation of liver inflammation-related parameters in CSAA- and CDAA-diet-fed rats. Representative photomicrographs showing the inflammation of CSAA and CDAA diet on liver histology in rats. Paraffin-embedded liver sections
were stained with H-E staining. Rats were fed CSAA diet and CDAA diet, co-administered with saline, or CSAA diet and CDAA diet, co-administered with nicotine, for 6 weeks. Arrows indicate the inflammatory foci in the liver. Original magnification, ×200 (A). The relative expression of TNF-α, CD68, IL1β, IL6, Bax and Cas3 mRNA in the liver was evaluated 6 weeks after feeding (B). The expression of target genes was normalized to that of 18s ribosomal RNA in each sample, and expressed as the magnitude of change relative to gene expression after 6 weeks of feeding CSAA diet co-administered with saline. Data are expressed as means ± SE of six to eight rats. (* p < 0.05, ** p < 0.01 compared with the respective groups).

https://doi.org/10.1371/journal.pone.0180475.g003

Fig 4. Evaluation of immunohistochemical staining of hepatic CD68-positive cells in CSAA- and CDAA-diet-fed rats. Representative photomicrographs showing the hepatic CD68-positive cells in CSAA- and CDAA-diet-fed rats co-administered the saline control or nicotine for 6 weeks. Arrows indicate CD68-positive cells. (A) Quantitative analysis of changes in the numbers of CD68-positive cells in the respective groups (B). Original magnification, ×100. Data are expressed as means ± SE of six to eight rats. (* p < 0.01 compared with the respective groups).

https://doi.org/10.1371/journal.pone.0180475.g004
Fig 5. Evaluation of liver fibrosis-related parameters in CSAA- and CDAA-diet-fed rats. Representative photomicrographs showing the fibrosis of CSAA and CDAA diet on liver histology in rats. Liver tissues were stained with Masson’s trichrome staining.
Rats were fed CSAA diet and CDAA diet, co-administered with saline, or CSAA diet and CDAA diet, co-administered with nicotine, for 6 weeks. Arrows indicate the hepatic fibrosis in the liver. Original magnification, ×100 (A). Quantitative analysis of changes in the Masson’s trichrome staining blue colored area in the respective groups (B). The expression of Acta2 was normalized to that of 18s ribosomal RNA in each sample, and expressed as the magnitude of change relative to gene expression after 6 weeks of feeding CSAA diet co-administered with saline (C). Evaluation of immunohistochemical staining of hepatic α-SMA-positive cells in CSAA- and CDAA-diet-fed rats co-administered the saline control or nicotine for 6 weeks. Arrows indicate α-SMA-positive cells (D). Quantitative analysis of changes in the number of α-SMA-positive cells in the respective groups (E). Data are expressed as means ± SE of six to eight rats. (*p < 0.05, **p < 0.01 compared with the respective groups).

Table 4. Effect of hepatic branch of vagotomy on CDAA diet-induced NASH model.

| Group              | n | Body Weight gain (g) | Food Intakes (g/day) | Serum TG (mg/dl) | Hepatic TG (mg/dl) | Hepatic FFA (mEq/l) | Serum ALT (IU/L) |
|--------------------|---|----------------------|----------------------|------------------|-------------------|-------------------|---------------|
| sham + saline      | 6 | 79 ± 3.1             | 12.9 ± 0.5           | 25.5 ± 1.5       | 652 ± 110         | 1.2 ± 0.4         | 194 ± 15      |
| sham + nicotine    | 6 | 68 ± 4.9a            | 10.1 ± 1.8a          | 23.3 ± 1.5       | 430 ± 15a         | 0.4 ± 0.1a        | 201 ± 9.2     |
| vagotomy + saline  | 6 | 55 ± 3.9b            | 9.1 ± 0.5b           | 35.1 ± 3.8a      | 394 ± 79a         | 0.7 ± 0.2a        | 175 ± 16      |
| vagotomy + nicotine| 6 | 63 ± 6.6a            | 9.3 ± 1.1a           | 37.5 ± 4.3a      | 402 ± 36a         | 0.9 ± 0.1a        | 181 ± 19      |

Data are expressed as means ± SEM; Statistical comparison were made using one-way ANOVA

a: significant different from sham + saline 6 weeks (p < 0.05)
b: significant different from sham + saline 6 weeks (p < 0.01)
Table 5. NAFLD activity scores (NAS) of rats with hepatic branch of vagotomy on CDAA diet-induced NASH model.

| Group                  | n  | steatosis        | inflammation | Hepatocyte ballooning |
|------------------------|----|------------------|--------------|-----------------------|
| sham + saline          | 6  | 2.667 ± 0.042    | 1.600 ± 0.225| 0.233 ± 0.033         |
| sham + nicotine        | 6  | 2.375 ± 0.139a   | 1.200 ± 0.256| 0.100 ± 0.038b        |
| vagotomy + saline      | 6  | 2.312 ± 0.051b   | 1.572 ± 0.325| 0.213 ± 0.113         |
| vagotomy + nicotine    | 6  | 2.229 ± 0.154    | 1.550 ± 0.253| 0.240 ± 0.132         |

Data are expressed as means ± SEM; Statistical comparison were made using one-way ANOVA

a: significantly different from sham + saline (p < 0.05)
b: significantly different from sham + saline (p < 0.01)

https://doi.org/10.1371/journal.pone.0180475.t005

Fig 6. Representative photomicrographs showing the effects of hepatic branch vagotomy and sham operation on CDAA-diet-induced hepatic steatosis in rats. Frozen liver sections were stained with Oil Red O (A). Quantitative analysis of changes in Oil Red O positive lesions in the respective groups (B). Original magnification, ×100. Data are expressed as means ± SE of six rats. (* p < 0.05 compared with the respective groups).

https://doi.org/10.1371/journal.pone.0180475.g006
expression of TNF-α, CD68, IL1β, and IL6 at the mRNA levels were significantly attenuated by nicotine, whereas hepatic expression of Bax and Cas3 tended to decrease (Fig 8A and 8B). Hepatic branch vagotomy could not change the hepatic inflammation; ballooning scores; expression of TNF-α, CD68, IL1β, IL6, Bax, and Cas3 at the mRNA level; or the number of CD68-positive cells compared to those in sham-operated saline-treated rats (Table 5, Fig 8A and 8B). Nicotine administration could not affect the hepatic inflammation; ballooning scores; expression of TNF-α, CD68, IL1β, IL6, Bax, and Cas3 at the mRNA levels; or the number of CD68-positive cells in vagotomized rats (Table 5, Fig 8A and 8B).

Discussion

In this study, we showed that continuous administration of nicotine improved CDAA diet-induced hepatic steatosis and inflammation, and decreased the levels of hepatic TG, FFA, and the number of CD68-positive macrophages. We also demonstrated that nicotine administration significantly reduced body weight gain and food intake in CDAA diet-fed rats. A previous report indicated that nicotine administration improves obesity, hepatic steatosis, and serum lipid profile by decreasing food intake in high fat diet (HFD)-induced obese rats [11].
Fig 8. Evaluation of hepatic inflammation-related parameters in vagotomized and sham-operated rats fed with the CDAA diet. Relative mRNA expressions of hepatic TNF-α, CD68, IL1β, IL6, Bax and Cas3 (A) were evaluated. The expression of target genes was normalized to that of 18s ribosomal RNA in each sample, and expressed as the magnitude of change relative to gene expression after 6 weeks of feeding CDAA diet co-administered with saline in sham-operated rats. Quantitative analysis of changes in CD68-positive cells in the respective groups (B). Data are expressed as means ± SE of six rats. (*p < 0.05, compared with the respective groups).

https://doi.org/10.1371/journal.pone.0180475.g008
Conversely, Friedman et al. showed that HFD, co-administered with nicotine, produced higher levels of lipid accumulation in the liver compared to those fed with HFD alone [18]. While Friedman et al. administered nicotine at a dose of 0.75 mg/kg, which could not change food intake, other investigators administered nicotine at doses of at least 1.5 mg/kg, which attenuates food intake [11, 18, 19]. These differences in the doses of nicotine may affect food intake in rodents.

Ghoshal et al. reported that choline-deficient methionine-low diet induced hepatic steatosis and necrosis in rats [20]. The CDAA diet has been modified from the choline-deficient methionine-low diet, and long-term administration of the CDAA diet has been shown to consistently induce the development of steatohepatitis and eventual fibrosis and cirrhosis of the liver [21]. The methionine and choline-deficient (MCD) diet, which is similar to the CDAA diet, also attenuates body weight gain and leads to the development of hepatic steatosis, inflammation, and fibrosis in rodents [22]. We showed that CDAA diet itself increases hepatic TG and FFA, and decreases serum levels of TG. Emerging evidence has suggested that FFA is an important source of hepatic TG content [23]. The accumulation of fat in the liver is affected by β-oxidation, de novo lipogenesis, and lipid excretion; however, the precise mechanisms underlying these processes are not elucidated [22]. The expression of ACOX1, which is a β-oxidation-related gene, was not changed by CDAA diet as well as by nicotine administration. SREBP1 plays a key role in hepatic de novo lipogenesis, and Elovl6 is also known as a target gene of the SREBP transcription factor family [24, 25]. We showed that nicotine administration attenuated the hepatic expression of SREBP1 at the mRNA level and tended to decrease Elovl6 expression at the mRNA level in CDAA-diet-fed rats, suggesting that nicotine administration attenuated de novo lipogenesis in the liver. ApoB is a protein related to the production of very low density lipoprotein (VLDL); it is an important molecule involved in TG excretion from hepatocytes [26]. MTTP, which is also a regulator of lipid excretion in hepatocytes, is involved in the production of VLDL [27]. We showed that CDAA diet alone attenuated hepatic apoB, but not MTTP, and they were not attenuated by nicotine administration. These results indicate that CDAA diet-induced increase in hepatic FFA and TG contents and decrease in serum TG content might be due to the attenuation of apoB, and nicotine administration is not involved in the excretion of VLDL from the liver.

The CDAA diet significantly increased hepatic inflammation, expression of TNF-α, IL1β, and IL6 at the mRNA level, and number of macrophages in the liver, whereas nicotine administration significantly attenuated these parameters. Since pro-inflammatory and anti-inflammatory cytokines were attenuated by nicotine, anti-inflammatory immune response might be altered. The altered abundance and composition of fat in the liver could modulate the biological activity of Kupffer cells, which are resident macrophages, and augment hepatic inflammation in vivo [28]. The number of Kupffer cells significantly increased in the liver during the initial weeks of feeding with MCD diet [28]. Increased number of Kupffer cells enhances the sensitivity to hepatotoxin, which in turn, stimulates the secretion of pro-inflammatory cytokines and chemokines, such as TNF-α. MCD diet-fed mice exhibit significant increase in the number of Kupffer cells, which secrete several pro-inflammatory cytokines, such as TNF-α, during the initial weeks of feeding with choline-deficient diet [28]. In the present study, the CDAA diet increases the number of macrophages and levels of pro-inflammatory cytokine genes; nicotine administration may attenuate this increase resulting in the reduction of hepatic inflammation. Emerging data have shown that a high rate of hepatocyte apoptosis in patients with NASH, with the magnitude of apoptosis correlating to hepatic inflammation, indicated that apoptosis could be involved in causing NASH [29]. It has been shown that Bcl-2 family members, including both anti-apoptotic and pro-apoptotic proteins, could be major candidates of cell apoptosis [30]. We showed that the expression of Bax, a pro-apoptotic gene, in the
liver was significantly augmented by CDAA diet, and it tended to increase Cas3, which is major effector caspase. Nicotine administration significantly attenuated CDAA-induced augmentation of Bax mRNA, and tended to decrease Cas3 mRNA levels. Nicotine might have a potential as the inhibitor of apoptotic signaling in NASH models. Although hepatic inflammation was attenuated by nicotine, serum ALT levels were not significantly changed. NASH can occur without an increase in the liver enzyme levels, and there may not be progression of NASH in patients with fatty liver and high level of liver enzymes [31]. In the present study, high rate of fat deposition in the liver might contribute to serum ALT elevation. Considering CDAA diet-induced hepatic fibrosis, nicotine administration attenuated hepatic fibrosis, Acta2 mRNA levels, and α-SMA positive cells. On the contrary, little is known about the effect of nicotine on stellate cell activation. Thus, it is speculated that the decrease in CDAA diet intake might contribute to the attenuation of stellate cell activation resulting in the reduction of hepatic fibrosis.

The hepatic branch of the vagus nerve plays an important role in regulating food intake [12]. Niijima et al. reported that the hepatoportal-central feedback system, acting via the hepatic branch of the vagus nerve, is an important pathway for sensing peripheral nutrients or chemicals that modulate the feeding activity [12]. Nicotine acts peripherally via the hepatic vagal afferents from nicotine sensors in the hepatoportal region [13]. In the present study, nicotine-induced inhibition of food intake was not changed in vagotomized rats, indicating that nicotine affects via the hepatic branch of the vagus nerve. The body weight reduction induced by CDAA diet is larger than that induced by vagotomy. CDAA diet-induced body weight reduction might be affected by the impairment of liver metabolism without reduction of food intake [21]. Since both vagotomy and CDAA diet alone induced body weight reduction, the level of nicotine-induced reduction of food intake required for reduction of body weight remains to be studied. We showed that hepatic branch vagotomy alone attenuated food intake during the administration of the CDAA diet, but did not change the hepatic expression of SREBP-1, Elovl6, and ACOX1 at the mRNA level. We also showed that nicotine could not reduce food intake and change the hepatic expression of SREBP-1, Elovl6, and ACOX1 at the mRNA level in vagotomized rats. These results indicate that the impairment of the hepatic vagal tone may affect food intake, but not de novo lipogenesis and β-oxidation in the liver. The hepatic expression of apoB, but not MTTP, at the mRNA level was augmented by hepatic branch vagotomy, indicating that impairment of the vagal tone may affect apoB-related hepatic excretion of TG from the liver.

While hepatic branch vagotomy reduced food intake, body weight gain, and hepatic steatosis, increase in CDAA diet-induced hepatic inflammation, inflammatory cytokines, and expression of apoptosis-related genes were not improved. The hepatic vagus nerve is composed of 20% efferent and 80% afferent fibers; it regulates hepatic circulation and glucose metabolism via efferent fibers, which send signals to the peripheral regions of the liver [32, 33]. The efferent vagal nerve attenuates an endotoxin-induced release of TNF-α from the Kupffer cells in the liver [34]. On the contrary, acetylcholine, which is the main neurotransmitter in the vagus nerve, reportedly suppresses the secretion of inflammatory cytokines via the α7-nicotinic acetylcholine receptor in the Kupffer cells [34]. α7-nicotinic acetylcholine receptors have been reported to be necessary in mediating activation of the cholinergic anti-inflammatory pathway by nicotine [34]. These findings helped us speculate that nicotine affects α7-nicotinic acetylcholine receptors, resulting in the attenuation of CDAA diet-induced inflammation. Hepatic vagotomy alone may impede the efferent vagal nerve-induced anti-inflammatory response.

In conclusion, nicotine attenuated food intake, body weight gain, hepatic steatosis, and inflammation in CDAA diet-fed rats via the hepatic branch of the vagus nerve. These findings
indicate that nicotine may have an inhibitory effect on steatohepatitis in the rodent model of NASH.

Acknowledgments
We would like to thank Dr Shiro Yokohama, Asahikawa Medical Center, Asahikawa, Hokkaido, Japan for the guidance of hepatic branch vagotomy in rats.

Author Contributions
Conceptualization: Hiroyuki Kanamori, Yukiomi Nakade.
Data curation: Hiroyuki Kanamori, Yukiomi Nakade, Taeko Yamauchi, Kazumasa Sakamoto, Tadahisa Inoue, Takaya Yamamoto, Yuji Kobayashi, Norimitsu Ishii.
Formal analysis: Kazumasa Sakamoto, Tomohiko Ohashi, Kiyoaki Ito, Yoshio Sumida, Haruhisa Nakao, Yoshitaka Fukuzawa.
Investigation: Hiroyuki Kanamori, Yukiomi Nakade.
Methodology: Hiroyuki Kanamori, Yukiomi Nakade.
Writing – original draft: Yukiomi Nakade.

References
1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005; 42(1):44–52. PMID: 15895401. https://doi.org/10.1002/hep.20734
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4):339–50. PMID: 18956290. https://doi.org/10.1055/s-0028-1091978
3. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007; 11(1):1–16, vii. Epub 2007/06/05. https://doi.org/10.1016/j.cld.2007.02.009 PMID: 17544966.
4. Wasada T, Kasahara T, Wada J, Jimba S, Fujimaki R, Nakagami T, et al. Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity. Metabolism. 2008; 57(7):990–5. Epub 2008/06/17. https://doi.org/10.1016/j.metabol.2008.02.015 PMID: 18558841.
5. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51(1):121–9. https://doi.org/10.1002/hep.23276 PMID: 19827166; PubMed Central PMCID: PMC2799538.
6. Grunberg NE. Bowen DJ, Morse DE. Effects of nicotine on body weight and food consumption in rats. Psychopharmacology. 1984; 83(1):93–8. PMID: 6429707.
7. Levin ED, Morgan MM, Galvez C, Ellison GD. Chronic nicotine and withdrawal effects on body weight and food and water consumption in female rats. Physiol Behav. 1987; 39(4):441–4. PMID: 3575490.
8. Liu RH, Mizuta M, Matsukura S. Long-term oral nicotine administration reduces insulin resistance in obese rats. Eur J Pharmacol. 2003; 458(1–2):227–34. Epub 2002/12/25. PMID: 12498930.
9. Hashimoto T, Yoneda M, Shimada T, Kurosawa M, Terano A. Intraperitoneal nicotine infusion in rats decreases hepatic blood flow through endothelin-1 and both endothelin A and endothelin B receptors. Toxicol Appl Pharmacol. 2004; 196(1):1–10. Epub 2004/03/31. https://doi.org/10.1016/j.taap.2003.09.004 PMID: 15050402.
10. Yuen ST, Gogo AR Jr., Luk IS, Cho CH, Ho JC, Loh TT. The effect of nicotine and its interaction with carbon tetrachloride in the rat liver. Pharmacol Toxicol. 1995; 77(3):225–30. Epub 1995/09/01. PMID: 8848888.
11. Seoane-Collazo P, Martinez de Morentin PB, Ferno J, Dieguez C, Nogueiras R, Lopez M. Nicotine improves obesity and hepatic steatosis and ER stress in diet-induced obese male rats. Endocrinology. 2014; 155(5):1679–89. https://doi.org/10.1210/en.2013-1839 PMID: 24517227.
12. Nijima A, Fukuda A, Taguchi T, Okuda J. Suppression of afferent activity of the hepatic vagus nerve by anomers of D-glucose. Am J Physiol. 1983; 244(5):R611–4. PMID: 6846569.
13. Niijima A, Miyata G, Sato T, Meguid MM. Hepato-vagal pathway associated with nicotine’s anorectic effect in the rat. Auton Neurosci. 2001; 93(1–2):48–55. https://doi.org/10.1016/S1566-0702(01)00328-9 PMID: 11695706.

14. Pulford KA, Sipos A, Cordell JL, Stross WP, Mason DY. Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol. 1990; 2(10):973–80. Epub 1990/01/01. PMID: 2078523.

15. Arai K, Kim K, Kaneko K, Iketani M, Otagiri A, Yamauchi N, et al. Nicotine infusion alters leptin and uncoupling protein 1 mRNA expression in adipose tissues of rats. Am J Physiol Endocrinol Metab. 2001; 280(6):E687–76. Epub 2000/05/15. PMID: 11350768.

16. Klein DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313–21. Epub 2005/06/25. https://doi.org/10.1002/hep.20701 PMID: 15915461.

17. Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, et al. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013; 48(4):491–503. https://doi.org/10.1007/s00535-012-0651-7 PMID: 22886508.

18. Friedman TC, Sinha-Hikim I, Parveen M, Najjar SM, Liu Y, Mangubat M, et al. Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice. Endocrinology. 2012; 153(12):5809–20. Epub 2012/10/25. https://doi.org/10.1210/en.2012-1750 PMID: 23093702; PubMed Central PMCID: PMC3512067.

19. Mangubat M, Lutfy K, Lee ML, Pulido L, Stout D, Davis R, et al. Effect of nicotine on body composition in mice. J Endocrinol. 2012; 212(3):317–26. Epub 2011/12/06. https://doi.org/10.1530/JOE-11-0350 PMID: 22138237; PubMed Central PMCID: PMC3444240.

20. Ghoshal AK, Ahluwalia M, Farber E. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am J Pathol. 1983; 113(3):309–14. PMID: 6650660; PubMed Central PMCID: PMC1916365.

21. Nakae D. Endogenous liver carcinogenesis in the rat. Pathol Int. 1999; 49(12):1028–42. PMID: 10632923.

22. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004; 40(1):47–51. Epub 2003/12/16. PMID: 14672613.

23. Barter PJ, Nestel PJ. Precursors of plasma triglyceride fatty acids in obesity. Metabolism. 1973; 22(6):779–83. Epub 1973/06/01. PMID: 4350847.

24. Yahagi N, Shimanoh, Hasty AH, Amemiy-Kudo M, Okazaki H, Tamura Y, et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem. 1999; 274(50):35840–4. PMID: 10585468.

25. Kumadaki S, Matsuzaka T, Kato T, Yahagi N, Yamamoto T, Okada S, et al. Mouse Elovil-6 promoter is an SREBP target. Biochim Biophys Res Commun. 2008; 368(2):261–6. https://doi.org/10.1016/j.bbrc.2008.01.075 PMID: 18226595.

26. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002; 35(4):898–904. https://doi.org/10.1053/jhep.2002.32527 PMID: 11915037.

27. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol. 2004; 40(5):781–6. Epub 2004/04/20. https://doi.org/10.1016/j.hep.2004.01.028 PMID: 15094225.

28. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology. 2004; 40(2):386–93. Epub 2004/09/16. https://doi.org/10.1002/hep.20302 PMID: 15368443.

29. Feldstein AE, Canbay A, Angulo P, Tanki M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003; 125(2):437–43. PMID: 12891546.

30. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999; 13(15):1899–911. PMID: 10444588.

31. Uslusoy HS, Nak SG, Gulmen M, Bilyiki Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World journal of gastroenterology: WJG. 2009; 15(15):1863–8. PMID: 19370784; PubMed Central PMCID: PMCPMC2670414. https://doi.org/10.3748/wjg.15.1863

32. Yoneda M, Watanobe H, Terano A. Central regulation of hepatic function by neuropeptides. J Gastroenterol. 2001; 36(6):361–7. PMID: 11428581.

33. Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005; 1(1):53–61. https://doi.org/10.1016/j.cmet.2004.11.001 PMID: 16054044.
34. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003; 421(6921):384–8. https://doi.org/10.1038/nature01339 PMID: 12508119.